Ramanan Laxminarayan

Director and Senior Fellow

Ramanan Laxminarayan directs the Center for Disease Dynamics, Economics & Policy. He is also a Senior Research Scholar and Lecturer at Princeton University. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He has worked to improve understanding of drug resistance as a problem of managing a shared global resource.

Laxminarayan has worked with the World Health Organization (WHO) and the World Bank on evaluating malaria treatment policy, vaccination strategies, the economic burden of tuberculosis, and control of non-communicable diseases. He has served on a number of advisory committees at WHO, Centers for Disease Control and Prevention, and the Institute of Medicine. In 2003-04, he served on the National Academy ofScience/Institute of Medicine Committee on the Economics ofAntimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. His work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC,NPR, Reuters, Science, Wall Street Journal, and National Journal.



10 Jul 2015

What can structured expert judgement teach us about intervention effectiveness?

27 May 2015

What is the estimated impact, cost, effectiveness and cost-effectiveness of a an artemisinin combination therapy (ACT) subsidy for malaria treatment targeted at children? How could leakage of the...

20 Apr 2015

How many children under the age of five died in sub-Saharan Africa in 2013 because of or associated with poor-quality antimalarial drugs?

22 Jan 2015

Does physician competition drive up antibiotic prescribing? How does the existence of urgent care and retail clinics affect antibiotic prescription rates across different socioeconomic strata?...

4 Dec 2014

What have studies that estimate the economic burden of antibiotic resistance contributed to our understanding of the issue? What are their limitations? What conclusions can be reached by...

4 Dec 2014

What is the cost-effectiveness of policies that expand the use of aspirin, injection streptokinase, beta-blockers, angiotensin-converting enzyme inhibitors, and statins for in India for treatment...

17 Nov 2014

How and how often do hospitals change courses of empirical antibiotic therapy? Does this change when they have diagnostic information from cultures or imaging?

12 Sep 2014

What are the best strategies for conserving the natural resource of antibiotic effectiveness?

10 Aug 2014

How would increasing immunization coverage and introducing a rotavirus vaccine affect the disease and financial burden of vaccine-preventable illnesses in India?